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We performed orthogonal technology comparisons of concurrent peripheral blood and biopsy tissue samples from 69 kidney transplant recipients who underwent comprehensive algorithm-driven clinical phenotyping. The sample cohort included patients with normal protocol biopsies and stable transplant (sTx) function (n = 25), subclinical acute rejection (subAR, n = 23), and clinical acute rejection (cAR, n = 21). Comparisons between microarray and RNA sequencing (RNA-seq) signatures were performed and demonstrated a strong correlation between the blood and tissue compartments for both technology platforms. A number of shared differentially expressed genes and pathways between subAR and cAR in both platforms strongly suggest that these two clinical phenotypes form a continuum of alloimmune activation. SubAR is associated with fewer or less expressed genes than cAR in blood, whereas in biopsy tissues, this clinical phenotype demonstrates a more robust molecular signature for both platforms. The discovery work done in this study confirms a clear ability to detect gene expression profiles for sTx, subAR, and cAR in both blood and biopsy tissue, yielding equivalent predictive performance that is agnostic to both technology and platform. Our data also provide strong biological insights into the molecular mechanisms underlying these signatures, underscoring their logistical potential as molecular diagnostics to improve clinical outcomes following kidney transplantation.
Introduction
The survival benefits of solid organ transplant (Tx) in the United States are well documented (1) but with little impact on long-term kidney graft survival despite significant improvements in short-term outcomes (2) (3) (4) . In the OPTN/SRTR 2013 Annual Data Report, kidney graft failure rates for deceased donor Tx were 2.7% at 6 mo, Moreover, after the first year, the accumulation of late acute rejection episodes doubles the total incidence from 11-15% to 25% by 5 years (5).
There is a pressing clinical need for more sensitive and specific objective surrogate markers to predict alloimmune graft injury to potentially inform management and improve outcomes (6, 7) . Serum creatinine is an insensitive and nonspecific marker of alloimmune kidney injury (8) . Although overimmunosuppression increases multiple drug-related risks (9) , underimmunosuppression increases risks of clinical acute rejection (cAR); potentially actionable subclinical acute rejection (subAR), defined by histologically determined acute rejection in the absence of renal dysfunction; and, ultimately, chronic rejection (CR), the leading immunological cause of longterm graft loss (10) (11) (12) . A molecular signature to detect subAR would substantially improve our ability to monitor patients following transplantation, to intervene early at a stage of immune-mediated rejection with minimal tissue injury and monitoring of response to this intervention, potentially reducing the development of interstitial fibrosis and tubular atrophy (IFTA). The development of IFTA leads to lower GFR (13) and graft failure (14) . IFTA can develop surprisingly early after Tx with %15% incidence at 3 mo to 30% at 1 year and 40% at 2 years (15) (16) (17) (18) . Studies revealed that treatment of subAR was beneficial and led to improved short- (12) and long-term (19) renal function, although no randomized clinical trial has tested this premise, primarily because molecular tests that can detect subAR are only now emerging. Consistent with our view of the importance of maintaining effective immunosuppression, we recently mapped gene expression signatures from histologically and clinically phenotyped kidney biopsies (20) . Biopsies of cAR and CR shared >85% of known immune or inflammatory pathways validated in the literature for cell-mediated rejection, revealing an arc of immune-mediated Tx injury. In parallel, subAR, found only by doing protocol biopsies is associated with the development of chronic injury/IFTA and worse graft function and survival (3, 10, 13, (16) (17) (18) (21) (22) (23) (24) (25) (26) .
We previously demonstrated, using microarray analyses, that peripheral blood whole-genome expression profiling in kidney Tx recipients can accurately distinguish patients with stable function and normal histology, cAR and histologic acute rejection, and acute dysfunction with no rejection (27) . Affymetrix DNA microarrays represent an established diagnostic testing technology approved by the U.S. Food and Drug Administration (FDA). Costs for DNA microarrays have dropped significantly over the past decade and, with improved workflows and analytical tools, are now comparable to other methods used routinely in commercial diagnostic laboratories. In parallel, rapid advances in next-generation sequencing (NGS) technologies provide a cost-effective high-throughput RNA sequencing (RNA-seq) approach and clear potential to enable even lower cost gene expression profiling and faster workflows than can be obtained today with DNA microarrays (28, 29) . Two of the most widely used RNAseq platforms, Illumina (Illumina Inc. San Diego, CA) and Ion Torrent (Thermo Fisher Scientific, Waltham, MA), have FDA-approved clinical diagnostic workflows.
As molecular technology platforms rapidly evolve, concerns have been raised that the ability to detect diagnostic and predictive gene signatures that were discovered and validated on one technology or platform may not necessarily carry over to others. This concern is particularly relevant as molecular biomarkers begin their journey toward becoming commercial, especially given differences between technologies in logistics such as cost, turnaround time, point of service, and the use of commercially available kits. There is a paucity of technical studies comparing DNA microarray and RNA-seq technologies and even fewer studies comparing their relative capabilities as diagnostic tools. Technical studies comparing gene expression detection by microarrays and RNA-seq technologies have shown good correlations (30) (31) (32) (33) . A recent study showed that microarray-based models and RNA-seq performed similarly in clinical end point prediction in %500 biopsies of primary human neuroblastomas (34) . To our knowledge, there are no studies comparing these orthogonal technologies in biopsydocumented, precisely phenotyped kidney Tx recipients.
We hypothesized that the ability to detect molecular signatures of cAR and subAR in both peripheral blood and biopsy tissue would be agnostic to the technology platform used to assess gene expression. To test this hypothesis, we profiled peripheral blood and biopsy tissue derived from 69 precisely phenotyped kidney Tx recipients (stable Tx [sTx] = 25, subAR = 23, cAR = 21) selected from the Northwestern University (NU) Comprehensive Transplant Center's biorepository. After removing technical outliers (GAPDH ratios >4 for microarrays and RNA-seq samples with total reads <1 million), gene expression profiles were obtained by Affymetrix DNA microarray (peripheral blood, n = 69; biopsies, n = 65; total, n = 134; Affymetrix, Santa Clara, CA). In parallel, RNA-seq was done on the biopsies of the same patient cohort using the Ion Torrent Proton sequencing platform (n = 65) and the matching peripheral blood on the Illumina NextSeq platform (n = 45). Thus, a total of 244 global gene expression profiles were obtained on three different commercial platforms and their approved workflows. Our data support the ability to detect signatures of sTx, subAR, and cAR in both blood and tissue compartments, yielding equivalent predictive performance, agnostic to the technology or platform used.
Materials and Methods

Patients and samples
The NU Comprehensive Transplant Center houses a large repository of samples (NU biorepository) from Tx recipients. Kidney Tx recipients at NU undergo surveillance biopsies at 3, 12, and 24 mo after transplantation or for-cause biopsies in response to renal dysfunction. All patients who undergo biopsies are approached to provide informed consent (NU institutional review board no. STU00025946) to enroll in our biorepository. In addition to blood samples (2.5 mL PAXgene tube; Qiagen, Valencia, CA), a biopsy core was obtained and stored in RNAlater (Thermo Fisher Scientific). Biopsy slides were read by local pathologists and by a central pathologist in a blinded fashion using Banff 2007 criteria (35) , and all pathology slides are digitally archived (Aperio Digital Scanner, Buffalo Grove, IL). The repository has the stored clinical and laboratory data for all patients. All samples for gene expression were derived from recipients who had clinical and laboratory data available, as well as a histologic assessment of their biopsies. All patients who participated in this study were >18 years of age and recipients of a primary or subsequent kidney Tx alone. Recipients of multiorgan or prior nonrenal Tx and patients with human immunodeficiency virus were excluded. Standard immunosuppression at NU consists of alemtuzumab induction with tacrolimus and mycophenolate maintenance (prednisone-free).
Definitions and algorithm used for precision clinical phenotyping of study participants Stable renal function was defined as serum creatinine <2.3 mg/dL and <20% variability in the last 3 measurements. Acute renal dysfunction was ≥20% increase in serum creatinine compared with the previous three measurements. Normal histology showed no rejection (no T cell-mediated or antibody-mediated rejection of borderline or higher) or other abnormal histology (Banff fibrosis scores of 0 or 1 for interstitial fibrosis and tubular atrophy and both interstitial inflammation and tubulitis scores of 0) on a surveillance biopsy from a patient with stable renal function. Central reads were used for the clinical phenotyping algorithm. The sTx group (n = 25) had (i) surveillance biopsy, (ii) stable renal function, and (iii) normal histology. Gene expression profiling and statistical analysis RNA was extracted using the PAXgene Blood RNA system (Qiagen) and Ambion GLOBINclear (Life Technologies, Carlsbad, CA). Regardless of the technology used, total RNA from biopsies was extracted using the AllPrep DNA\RNA|Protein extraction kits (Qiagen). Ribosomal clearance was performed on all sequencing samples with the GeneRead rRNA Depletion Kit (Qiagen).
DNA microarrays: Affymetrix Human HT-HG U133 Plus 2.0 PM GeneChips (plate format) were used for gene expression in blood and biopsies. Biotinylated cRNA was prepared with Affymetrix GeneChip 3' IVT Plus kit., and all samples were run on the Affymetrix GeneTitan MC instrument. The primary transcript-detection method is hybridization and detection of fluorescently labeled cRNA to custom 23mer DNA probes.
Ion Torrent sequencing: RNA-seq of biopsies was done using the Ion Torrent Proton II (Thermo Fisher). Briefly, 50 ng RNA was used to generate sequencing libraries. RNA concentration was assessed using the Qubit RNA BR Assay kit (Bio-Rad, Hercules, CA). Sequencing libraries were generated using the Ion AmpliSeq Transcriptome Human Gene Expression Kit (Thermo Fisher) and bar coded using Ion Express bar codes. The cDNA library quality was assessed using the Agilent 2200 TapeStation System and the High Sensitivity D1000 ScreenTape System (Agilent Technologies, Santa Clara, CA). Templates were run on the Ion PI v3 chips using the Ion Chef system and Hi-Q Chef kits. Sequencing depth per sample was 12 million genome-aligned reads. The primary transcript-detection strategy depends on using Ion Torrent's custom designed primers targeting multiple exons for all known protein coding genes.
Illumina sequencing: All blood samples for RNA-seq were profiled using an Illumina NextSeq instrument (Illumina Inc). Total RNA was converted to cDNA using Ovation RNA-seq kits (NuGEN, San Carlos, CA) and S1 endonuclease digestion (Promega, Madison, WI) (36) . Digested cDNA libraries were end-repaired, A-tailed, and indexed adapter ligated. Ligation product was purified on Agencourt AMPure XP beads (Beckman Coulter Genomics, Carlsbad, CA) followed by 2% agarose size selection.
Purified product was amplified for 15 polymerase chain reaction (PCR) cycles, and size selection was repeated. Libraries were assessed on an Agilent Bioanalyzer and quantitated by Quant-iT ds DNA BR Assay kits (Invitrogen, Carlsbad, CA) and a Qubit Fluorimeter (Invitrogen). Cluster generation and 100-base pair single-end read sequencing was done following the manufacturer's instructions. Sequencing depth per sample was 15 million genome-aligned reads. The primary transcript detection strategy is capture of the cDNAs clusters on a plastic surface, followed by brief PCR amplification and incorporation of fluorescently tagged dNTPs guided by transcript sequences. All expression data have been deposited to the National Institutes of Health (NIH) Gene Expression Omnibus repository.
Statistical methodologies
Microarray signals were normalized with frozen robust multiarray analysis (37) . Predictions were done using the Support Vector Machines (SVM) algorithm implemented in R using the caret package (38) . Diagnostic performance was based on retrospective prediction of known clinical phenotypes. Predictive accuracy was calculated using the formula (TP + TN) / (TP + FP + FN + TN), where TP indicates true positive, TN indicates true negative, FP indicates false positive, and FN indicates false negative. Diagnostic metrics included sensitivity, specificity, and area under the curve (AUC). Clinical study parameters were tested by multivariate logistic regression with an adjusted (Wald test) p-value and false discovery rate (FDR) calculation. Results were classified at three levels of statistical confidence: FDR <10%, p < 0.005, and p < 0.05. Pathways were mapped using Ingenuity Pathway Analysis (IPA; Qiagen).
Results
Clinical phenotypes and other patient characteristics
Peripheral blood and biopsy tissue samples were analyzed for gene expression from 69 kidney Tx recipients enrolled at the time of biopsy into the NU biorepository, who had undergone algorithm-driven precise clinical phenotyping (sTx, n = 25; subAR, n = 23; cAR, n = 21). The mean age was 49.3 years (range 22-71 years), 35% were female, and 52% were deceased donor recipients. Blood was collected at the time of biopsy in all cases. The mean number of days after Tx to the time of biopsy was 288 days (range 8-748 days) for subAR, 268 days (range 84-2228 days) for sTx, and 921 days (range 15-2876 days) for cAR. All clinical characteristics of the study population are given in Table 1 . Given various technical sample issues, the final breakdowns of samples used in this study are shown in Table S1 .
Classifiers and predictive performance Analyses of two-class (phenotype) comparisons were performed at three levels of statistical confidence: (i) stringent FDR <10%, (ii) conservative p < 0.005, and (iii) relaxed p < 0.05. Less stringent statistical limits are justified for smaller data sets for early stage discovery studies such as ours (69 participants; 244 total gene expression profiles). Table 2 shows the differentially expressed genes in blood and biopsies comparing transcript detection by microarrays and RNA-seq. Statistically significant numbers of differentially expressed genes are observed between cAR versus sTx and subAR versus cAR in both blood and biopsies. However, fewer differentially expressed genes were observed for subAR versus sTx in the peripheral blood by either microarrays or RNA-seq. In contrast, significant and equivalent numbers of genes were detected for subAR versus sTx in the biopsies.
To measure the correlation of differential expression, blood versus biopsies and microarrays versus RNA-seq, M (log ratios) and A (mean/average) scale plots were created ( Figures 1A-B) . Principal components analysis (Figure 2) shows that the differentially expressed genes in the biopsies, by virtue of their larger numbers and robust statistical significance, separate phenotypes more efficiently than blood for both platforms.
The performance of optimal classifiers based on the differentially expressed genes to predict the precision phenotypes was tested next. Classifiers were selected using a preselected set of features (probe sets) picked by the SVM algorithm in an unbiased fashion and run using both cross validation and bootstrapping. A number of methods for are available, but we used two common methods for internal validation using data-splitting fivefold: cross-validation (Table 3) , which splits the data into smaller cohorts, and the more rigorous bootstrapping (Table 4) , which leverages the whole data set. Classifiers were selected using a preselected set of features (probe sets) picked by the SVM algorithm in an unbiased fashion and run using both cross-validation and bootstrapping.
The best microarray classifier sets for peripheral blood using fivefold cross-validation predicted cAR versus sTx and subAR versus sTx with AUCs of 0.95, respectively. By the rigorous bootstrapping, the AUCs were 0.96 and 0.82, respectively. The best microarray classifier sets for the biopsies using fivefold cross-validation predicted cAR versus sTx and subAR versus sTx with AUCs of 1.00 and 0.99, respectively. By bootstrapping, the AUCs were 1.00 and 0.95, respectively.
The best RNA-seq classifier sets for peripheral blood using fivefold cross-validation predicted cAR versus sTx and subAR versus sTx with AUCs of 1.00 and 0.96, respectively. By bootstrapping, the AUCs were 1.00 and 0.87, respectively. The best RNA-seq classifier sets for the biopsies using fivefold cross-validation predicted cAR This first analysis comparing DNA microarrays with RNAseq suggests that RNA-seq may have a slight performance advantage that must be tested with multiple independent external cohorts, as data overfitting is always possible with internal validation methods. Receiver operating characteristic curves using the best performing classifiers for the microarray classifier sets by bootstrapping are shown in Figure S1 , and RNA-seq classifiers are shown in Figure S2 .
Differentially expressed genes present in both the blood and biopsies regardless of technology platform (shared genes) The differentially expressed shared genes for blood and biopsies by microarrays and RNA-seq are shown in Table 5 . The cAR versus sTx and subAR versus sTx comparisons were significant at p < 0.05. cAR versus sTx was also significant at a more stringent cutoff of FDR <10%. Even though genes are shared between blood and biopsy, the directionality of change (up-or downregulation in a specific comparison) may not be the same. Thus, the simple observation of a shared gene in two compartments does not mean the function is biologically the same. Indeed, half the shared genes showed the opposite fold-change direction for all comparisons, suggesting that the blood and the biopsy are truly independent immunological compartments with distinctly different biological processes (Table 6 ). We tested the hypothesis that subAR is a state of alloimmune/inflammatory rejection at which point the amount of tissue injury has not exceeded the threshold to cause clinical Tx dysfunction (i.e. acute renal dysfunction; decreased estimated GFR). If this were true, one prediction would be that subAR is a milder form of cAR manifesting relatively lower gene expression levels for genes upregulated in cAR and higher expression of genes downregulated in cAR.
Therefore, we plotted the subset of shared genes in the comparisons of cAR versus sTx and subAR versus sTx in both blood and biopsies. As shown in Figures 3(A) -(D), the majority of the shared cAR versus sTx genes (green dots) that had the same fold-change directionality (up-or downregulated) and had greater fold change than the same genes in subAR versus sTx.
Pathway mapping of shared and unique genes between blood and biopsies Pathway mapping of blood versus biopsy genes was done using IPA. A p < 0.05 and >10 molecules that were differentially expressed in each pathway filter were used. We combined the microarray and RNA-seq data using the following criteria: (i) Genes for mapping were composed of shared genes; (ii) shared genes had the same fold-change direction. For the cAR versus sTx comparison, there were 109 shared pathways between blood and biopsy. The top 10 shared pathways ranked by p-value were mitochondrial dysfunction, B cell receptor, oxidative phosphorylation, protein ubiquitination, Nuclear factor of activated T-cells (NFAT), Tec kinase, Hepatocyte growth factor, CD28, PI3K/AKT, and glucocorticoid receptor signaling. In contrast, there were only eight shared pathways between blood and biopsy for the subAR versus sTx comparison. These were B cell receptor, T lymphocyte apoptosis, CD28, CTLA4 in cytotoxic T lymphocytes, leukocyte extravasation, phospholipase C, NFAT regulation of the immune response, and T cell receptor signaling (Table 7 ).
An overall analysis of cAR versus sTx and subAR versus sTx in both blood and biopsies revealed six key shared pathways (CD28 in T helper cells, CTLA4 in cytotoxic T lymphocytes, leukocyte extravasation, phospholipase C, NFAT in regulation of the immune response, and T cell receptor signaling). Even though these pathways are shared, there were molecules that mapped to the same pathways but were not identical. In the CD28 signaling pathway, for example, the CD28 molecule was only differentially expressed in the blood, but PIK3CA was seen in both tissues (Table S2) .
Discussion
We performed orthogonal technology comparisons of gene expression from both peripheral blood and biopsy tissue compartments concurrently obtained from 69 algorithm-driven clinically phenotyped kidney Tx recipients. We used two high-throughput global gene expression profiling technologies: microarray analysis using Affymetrix gene arrays and RNA-seq using both the Ion Torrent and Illumina platforms.
The results of the study demonstrate, first, that diagnostic performance based on the ability to retrospectively predict known clinical phenotypes using SVM were equivalent across technologies and platforms (Affymetrix DNA microarrays, Ion Torrent, and Illumina RNA-seq). Second, optimal classifiers selected using the SVM algorithm were different, reflecting the technical differences inherent in the chemistries for detection and quantification of gene expression across platforms. Third, despite significant overlap in the differentially expressed genes between the blood and biopsies, directionality of these changes differed considerably between compartments, suggesting that these represent distinct immune compartments. Fourth, alloimmune/inflammatory pathway mapping to compare differential gene expression in blood and biopsies revealed a number of different genes in each of these two compartments, but these mapped to similar pathways across all technologies. Consequently, our ability to detect signatures for sTx, subAR, and cAR in both compartments appears to be agnostic to the technology or platform used, and equivalent predictive performance metrics were obtained. These data suggest that the ability to develop signatures on one platform should result in a similar ability to develop an equivalent performing signature on another, in response to potential logistical and commercial advantages of new and evolving technologies. To our knowledge, this study is the first to compare orthogonal technologies for molecular diagnostics using RNA-based differential gene expression in kidney Tx recipients.
We addressed important and often overlooked aspects of biomarker discovery. To avoid overtraining, we used both fivefold cross-validation and a full leave-one-out bootstrapping methodology. Of interest, the actual optimal classifiers were different for each platform; therefore, workflows will need to be developed for different technology platforms for introduction into clinical practice. Nonetheless, we showed that they give equivalent predictive performances for sTx, cAR, and subAR. Consequently, decisions made by clinical laboratories regarding which commercial test to use will likely be based on issues other than performance, such as test costs, details of workflow, cost of equipment and its maintenance, and the choice of data analysis pipelines to report results to a clinician. This outcome provides a strong comfort level for the use of microarrays or RNA-seq and of specific RNAseq platforms to develop predictive molecular biomarkers to diagnose and predict rejection.
It also appears that the peripheral blood changes may not be as robust as the changes at the tissue site of injury. The subAR signature in the peripheral blood appears to signal a milder form of cAR, consistent with previous data showing similar cellular processes between subAR and cAR (39) . Our data show a high level of sharing of differentially expressed genes and pathways between cAR and subAR. SubAR is represented by fewer and less expressed genes than cAR in blood. This is further supported by our analysis that 65-70% of subAR cases are detected by using a signature that was discovered for the diagnosis of cAR in blood (Affymetrix DNA microarrays; data not shown).
Traditional invasive biopsy-based diagnoses are vulnerable to the challenge of sampling errors and differences between the interpretations of individual pathologists (40, 41) . The 2007 Banff group previously defined and subsequently refined the pathologic criteria for postimplantation biopsies using the same criteria for implantation biopsies (35) .The interobserver concordance that measures reproducibility between pathologists showed that graft correlates such as acute tubular injury, inflammation in nonscarred areas (Banff interstitial inflammation score), and interstitial inflammation had the poorest concordance rates. The Banff working group on preimplantation biopsies recently concluded that significant limitations remain (42) . Despite concerns about histology being the gold standard, as well as the ongoing debate about the virtues of local versus central histology reads, we chose to use the central read for the histology component of our clinical phenotype algorithms. We believe that we may be able to demonstrate a better correlation between the molecular phenotype of the biopsy with long-term outcome compared with either the local or central histology reads. The pros and cons of the currently used platforms to profile rejection phenotypes and to build predictive models have been nicely discussed in a review of genomics in understanding and prediction of clinical renal Tx injury (43) . In this study, the slightly better performance of the RNA-seq classifiers was attributed to low signal-tonoise ratio compared with microarrays and a larger dynamic range of expression levels over which transcripts can be reliably detected, as shown in other studies (39, 44) . Similarly, the sequencing depth in this study was lower than the generally agreed consensus of %30-40 million reads (44) that is suited to detect major splice isoforms, which was not our focus. We tested the power of the detected genes to discriminate the clinical phenotypes and to compare how well the signatures perform.
We also believe that it is important to map the gene networks to show that our analyses are not simply statistical but also founded in the biology of rejection and tissue injury. Despite shared genes, the comparison of the blood and biopsy expression profiles also shows clear differences. Our results demonstrate that tissue injury and damage begin in the graft and that the blood reveals genes unique to that compartment but that nevertheless inform the prediction of clinical phenotypes, consistent with our previous work and that of others (20, 27, (45) (46) (47) (48) (49) .
Although classifiers cannot be locked across technologies or platforms, the predictive performance appears to be equivalent and agnostic to the platform, suggesting the ability to develop signatures across platforms with relatively little technical variation and estimation of expression levels of RNA transcripts (50), as these become more robust and cost-effective (31).
This study has some limitations. The sample size was small and appropriate only for a discovery study, as intended, but we demonstrated with the bootstrapping methodology-the closest approximation of real error estimates in a simulation of independent cohorts-no appreciable deterioration of the predictive metrics for our signatures. Although we provided internal validation through widely accepted data-splitting cross-validation bootstrapping methods, we did not perform external independent validation of the signatures described. This was not the intended goal of this study. In fact, these studies are ongoing in the NIH-funded CTOT study of 300 Tx recipients followed serially for 2 years. Instead, our primary objective was to assess whether different technology platforms could be used to detect differential gene expression profiles that signal immune activation in both peripheral blood and biopsy tissue. We also acknowledge that our population had no cases of pure antibody-mediated rejection, although 23% of the cAR biopsy samples showed C4d-positive staining. In addition, the majority of patients were white; however, we successfully validated our biopsy molecular phenotypes in a Brazilian cohort of 94 patients of significantly different racial and ethnic backgrounds (48) , suggesting strong unifying immune mechanisms despite differences in racial, ethnic, and genetic backgrounds.
In conclusion, we present a proof-of-concept discovery study that evaluates the predictive performance and profiling capabilities of two complementary techniques of global gene expression profiling for discrimination of three post-Tx phenotypes. To our knowledge, this is also the first study of kidney Tx rejection that has performed peripheral blood and biopsy profiling and compared them.
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